Investigational drugs for the treatment of endometriosis, an update on recent developments

References

• von Theobald P, Cottenet J, Iacobelli S, et al. Epidemiology of endometriosis in France: a large, nation-wide study based on hospital discharge data. (2314-6141 (Electronic)).
   Google Scholar
• Vercellini P, Vigano P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261–275.
   PubMed Web of Science ®Google Scholar
• Eisenberg VH, Weil C, Chodick G, et al. Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. BJOG : an international journal of obstetrics and gynaecology. 2018 Jan;125(1):55-62.
   Google Scholar
• Morotti M, Remorgida V, Venturini PL, et al. Endometriosis in menopause: a single institution experience. Arch Gynecol Obstet. 2012;286(6):1571–1575.
   PubMed Web of Science ®Google Scholar
• Guerriero S, Condous G, Van den Bosch T, et al. Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2016 Sep;48(3):318-32.
   Google Scholar
• Van Holsbeke C, Van Calster B, Guerriero S, et al. Endometriomas: their ultrasound characteristics. Ultrasound Obstet Gynecol. 2010;35(6):730–740.
   PubMed Web of Science ®Google Scholar
• Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–412.
   PubMed Web of Science ®Google Scholar
• Duffy JM, Arambage K, Correa FJ, et al. Laparoscopic surgery for endometriosis. Cochrane Database Syst Rev. 2014;4:CD011031.
   Google Scholar
• Tafi E, Leone Roberti Maggiore U, Alessandri F, et al. Advances in pharmacotherapy for treating endometriosis. Expert Opin Pharmacother. 2015;16(16):2465–2483.
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Ferrero S. Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. Expert Opin Drug Metab Toxicol. 2018Apr 10:1-17.
   Web of Science ®Google Scholar
• Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2017;1:CD004753.
   PubMedGoogle Scholar
• Menakaya U, Infante F, Condous G. Consensus on current management of endometriosis. Hum Reprod. 2013;28(11):3162–3163.
   PubMed Web of Science ®Google Scholar
• Schweppe KW. Current place of progestins in the treatment of endometriosis-related complaints. Gynecol Endocrinol. 2001;15(Suppl 6):22–28.
   PubMedGoogle Scholar
• Upson K, Allison KH, Reed SD, et al. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am J Obstet Gynecol. 2012;207(1):36e1–8.
   Web of Science ®Google Scholar
• Ferrero S, Alessandri F, Racca A, et al. Treatment of pain associated with deep endometriosis: alternatives and evidence. Fertil Steril. 2015;104(4):771–792.
   PubMed Web of Science ®Google Scholar
• Abu Hashim H. Gonadotrophin-releasing hormone analogues and endometriosis: current strategies and new insights. Gynecol Endocrinol. 2012;28(4):314–321.
   PubMed Web of Science ®Google Scholar
• Perricos A, Wenzl R. Efficacy of elagolix in the treatment of endometriosis. Expert Opin Pharmacother. 2017;18(13):1391–1397.
   PubMed Web of Science ®Google Scholar
• Taniguchi F, Higaki H, Azuma Y, et al. Gonadotropin-releasing hormone analogues reduce the proliferation of endometrial stromal cells but not endometriotic cells. Gynecol Obstet Invest. 2013;75(1):9–15.
   PubMed Web of Science ®Google Scholar
• Altintas D, Kokcu A, Tosun M, et al. Comparison of the effects of cetrorelix, a GnRH antagonist, and leuprolide, a GnRH agonist, on experimental endometriosis. J Obstet Gynaecol Res. 2008;34(6):1014–1019.
   PubMed Web of Science ®Google Scholar
• Küpker W, Felberbaum RE, Krapp M, et al. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online. 2002;5(1):12–16.
   PubMedGoogle Scholar
• Struthers RS, Chen T, Campbell B, et al. Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902). J Clin Endocrinol Metabolism. 2006;91(10):3903–3907.
   PubMed Web of Science ®Google Scholar
• Diamond MP, Carr B, Dmowski WP, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014;21(3):363–371.
   PubMed Web of Science ®Google Scholar
• Carr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014;21(11):1341–1351.
   PubMed Web of Science ®Google Scholar
• Taylor HS, Giudice LC, Lessey BA, et al. Treatment of Endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40.
   PubMed Web of Science ®Google Scholar
• Nakata D, Masaki T, Tanaka A, et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014;723:167–174.
   PubMed Web of Science ®Google Scholar
• Blakemore J, Naftolin F. Aromatase: contributions to physiology and disease in women and men. Physiology (Bethesda). 2016;31(4):258–269.
   PubMed Web of Science ®Google Scholar
• Noble LS, Simpson ER, Johns A, et al. Aromatase expression in endometriosis. J Clin Endocrinol Metab. 1996;81(1):174–179.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Remorgida V, Maganza C, et al. Aromatase and endometriosis: estrogens play a role. Ann N Y Acad Sci. 2014;1317:17–23.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Gillott DJ, Venturini PL, et al. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011;9:89.
   PubMed Web of Science ®Google Scholar
• Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–412.
   PubMed Web of Science ®Google Scholar
• Hefler LA, Grimm C, Van Trotsenburg M, et al. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril. 2005;84(4):1033–1036.
   PubMed Web of Science ®Google Scholar
• Buggio L, Lazzari C, Monti E, et al. “Per vaginam” topical use of hormonal drugs in women with symptomatic deep endometriosis: a narrative literature review. Arch Gynecol Obstet. 2017;296(3):435–444.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Venturini PL, Gillott DJ, et al. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. Reproductive biology and endocrinology: RB&E. 2011 Jun 21;9:88.
   Google Scholar
• Ferrero S, Leone Roberti Maggiore U, Scala C, et al. Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies. Arch Gynecol Obstet. 2013;287(3):447–453.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Remorgida V, Venturini PL, et al. Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. Eur J Obstetrics Gynecol Reprod Biol. 2014;174(1):117–122.
   PubMedGoogle Scholar
• Seal SL, Kamilya G, Mukherji J, et al. Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review. Fertil Steril. 2011;95(1):291.e15-.e18.
   Web of Science ®Google Scholar
• Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004;19(1):160–167.
   PubMed Web of Science ®Google Scholar
• Roghaei MA, Tehrany HG, Taherian A, et al. Effects of letrozole compared with danazol on patients with confirmed endometriosis: a randomized clinical trial. Int J Fertil Sterility. 2010;4(2):67–72.
   Web of Science ®Google Scholar
• Alborzi S, Hamedi B, Omidvar A, et al. A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. Arch Gynecol Obstet. 2011;284(1):105–110.
   PubMed Web of Science ®Google Scholar
• De Villiers TJ. Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. Climacteric. 2010;13(3):210–218.
   PubMed Web of Science ®Google Scholar
• Kulak J Jr., Fischer C, Komm B, et al. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology. 2011;152(8):3226–3232.
   PubMed Web of Science ®Google Scholar
• Sakr S, Naqvi H, Komm B, et al. Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment. Endocrinology. 2014;155(4):1489–1497.
   PubMed Web of Science ®Google Scholar
• Naqvi H, Sakr S, Presti T, et al. Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model. Biol Reprod. 2014;90(6):121.
   PubMed Web of Science ®Google Scholar
• Yao Z, Shen X, Capodanno I, et al. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J Invest Surg. 2005;18(4):177–183.
   PubMed Web of Science ®Google Scholar
• Altintas D, Kokcu A, Kandemir B, et al. Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. Eur J Obstet Gynecol Reprod Biol. 2010;150(1):84–87.
   PubMed Web of Science ®Google Scholar
• Stratton P, Sinaii N, Segars J, et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol. 2008;111(1):88–96.
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Meduri G, Bouchard P, et al. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005;11(3):293–307.
   PubMed Web of Science ®Google Scholar
• Wagenfeld A, Saunders PT, Whitaker L, et al. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin Ther Targets. 2016;20(9):1045–1054.
   PubMed Web of Science ®Google Scholar
• Wolf JP, Hsiu JG, Anderson TL, et al. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Fertil Steril. 1989;52(6):1055–1060.
   PubMed Web of Science ®Google Scholar
• Slayden OD, Zelinski-Wooten MB, Chwalisz K, et al. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum Reprod. 1998;13(2):269–277.
   PubMed Web of Science ®Google Scholar
• Hodgen GD, van Uem JF, Chillik CF, et al. Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum Reprod. 1994;9(Suppl 1):77–81.
   PubMedGoogle Scholar
• Grow DR, Williams RF, Hsiu JG, et al. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab. 1996;81(5):1933–1939.
   PubMed Web of Science ®Google Scholar
• Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 2010;82(5):442–452.
   PubMed Web of Science ®Google Scholar
• Kettel LM, Murphy AA, Morales AJ, et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril. 1996;65(1):23–28.
   PubMed Web of Science ®Google Scholar
• Kettel LM, Murphy AA, Mortola JF, et al. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril. 1991;56(3):402–407.
   PubMed Web of Science ®Google Scholar
• Kettel LM, Murphy AA, Morales AJ, et al. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod. 1994;9(Suppl 1):116–120.
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Garg R, Brenner RM, et al. Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. Ann N Y Acad Sci. 2002;955: 373–388. discussion 89-93, 96-406.
   PubMed Web of Science ®Google Scholar
• Madauss KP, Grygielko ET, Deng SJ, et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol. 2007;21(5):1066–1081.
   PubMed Web of Science ®Google Scholar
• Glace L, Grygielko ET, Boyle R, et al. Estrogen-induced stromal cell-derived factor-1 (SDF-1/Cxcl12) expression is repressed by progesterone and by selective estrogen receptor modulators via estrogen receptor alpha in rat uterine cells and tissues. Steroids. 2009;74(13–14):1015–1024.
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005;26(3):423–438.
   PubMed Web of Science ®Google Scholar
• Tosti C, Biscione A, Morgante G, et al. Hormonal therapy for endometriosis: from molecular research to bedside. Eur J Obstet Gynecol Reprod Biol. 2017;209:61–66.
   PubMed Web of Science ®Google Scholar
• Huniadi CA, Pop OL, Antal TA, et al. The effects of ulipristal on Bax/Bcl-2, cytochrome c, Ki-67 and cyclooxygenase-2 expression in a rat model with surgically induced endometriosis. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):360–365.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. Expert Opin Drug Metab Toxicol. 2018;14(1):107–116.
   PubMed Web of Science ®Google Scholar
• Bruner-Tran KL, Zhang Z, Eisenberg E, et al. Down-regulation of endometrial matrix metalloproteinase-3 and −7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget. J Clin Endocrinol Metab. 2006;91(4):1554–1560.
   PubMed Web of Science ®Google Scholar
• Hey-Cunningham AJ, Peters KM, Zevallos HB, et al. Angiogenesis, lymphangiogenesis and neurogenesis in endometriosis. Front Biosci (Elite Ed). 2013;5:1033–1056.
   PubMedGoogle Scholar
• Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update. 2012;18(6):682–702.
   PubMed Web of Science ®Google Scholar
• Taylor RN, Yu J, Torres PB, et al. Mechanistic and therapeutic implications of angiogenesis in endometriosis. Reprod Sci. 2009;16(2):140–146.
   PubMed Web of Science ®Google Scholar
• Morotti M, Valenzano Menada M, Venturini PL, et al. Bevacizumab in endometrial cancer treatment. Expert Opin Biol Ther. 2012;12(5):649–658.
   PubMed Web of Science ®Google Scholar
• Ricci AG, Olivares CN, Bilotas MA, et al. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reprod Sci. 2011;18(7):614–622.
   PubMed Web of Science ®Google Scholar
• Soysal D, Klzlldaʇ S, Saatll B, et al. A novel angiogenesis inhibitor bevacizumab induces apoptosis in the rat endometriosis model. Balkan J Med Genet. 2014;17(2):73–80.
   PubMed Web of Science ®Google Scholar
• Kebapcilar AG, Ilhan TT, Dursunoglu D, et al. Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats. Gynecol Endocrinol. 2017;33(12):923–927.
   PubMed Web of Science ®Google Scholar
• Nap AW, Griffioen AW, Dunselman GAJ, et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metabolism. 2004;89(3):1089–1095.
   PubMed Web of Science ®Google Scholar
• Moggio A, Pittatore G, Cassoni P, et al. Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. Fertil Steril. 2012;98(6):1521–30.e2.
   PubMed Web of Science ®Google Scholar
• Ozer H, Boztosun A, Açmaz G, et al. The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model. Reprod Sci. 2013;20(1):26–32.
   PubMed Web of Science ®Google Scholar
• Yildiz C, Kacan T, Akkar OB, et al. Effects of pazopanib, sunitinib, and sorafenib, anti-VEGF agents, on the growth of experimental endometriosis in rats. Reprod Sci. 2015;22(11):1445–1451.
   PubMed Web of Science ®Google Scholar
• Pala HG, Erbas O, Pala EE, et al. The effects of sunitinib on endometriosis. J Obstet Gynaecol. 2015;35(2):183–187.
   PubMedGoogle Scholar
• Guba M, Von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128–135.
   PubMed Web of Science ®Google Scholar
• Laschke MW, Elitzsch A, Scheuer C, et al. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol. 2006;149(2):137–144.
   PubMed Web of Science ®Google Scholar
• Leconte M, Nicco C, Ngo C, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol. 2011;179(2):880–889.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33(8):930–936.
   PubMed Web of Science ®Google Scholar
• Lin M, Weng H, Wang X, et al. The role of tissue factor and protease-activated receptor 2 in endometriosis. Am J Reprod Immunol. 2012;68(3):251–257.
   PubMed Web of Science ®Google Scholar
• Krikun G, Hu Z, Osteen K, et al. The immunoconjugate “icon” targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol. 2010;176(2):1050–1056.
   PubMed Web of Science ®Google Scholar
• Basu S, Dasgupta PS. Alteration of dopamine D2 receptors in human malignant stomach tissue. Dig Dis Sci. 1997;42(6):1260–1264.
   PubMed Web of Science ®Google Scholar
• Basu S, Sarkar C, Chakroborty D, et al. Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res. 2004;64(16):5551–5555.
   PubMed Web of Science ®Google Scholar
• Eljarmak D, Lis M, Cantin M, et al. Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma. Horm Res. 1985;21(3):160–167.
   PubMedGoogle Scholar
• Delgado-Rosas F, Gomez R, Ferrero H, et al. The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis. Reproduction (Cambridge, England). 2011;142(5):745–755.
   PubMed Web of Science ®Google Scholar
• Novella-Maestre E, Carda C, Noguera I, et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod. 2009;24(5):1025–1035.
   PubMed Web of Science ®Google Scholar
• Gomez R, Abad A, Delgado F, et al. Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia. Fertil Steril. 2011;95(3):882–8 e1.
   PubMed Web of Science ®Google Scholar
• Allen C, Hopewell S, Prentice A, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2009;2:CD004753.
   PubMed Web of Science ®Google Scholar
• Machado DE, Berardo PT, Landgraf RG, et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model. Fertil Steril. 2010;93(8):2674–2679.
   PubMed Web of Science ®Google Scholar
• Olivares C, Bilotas M, Buquet R, et al. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hum Reprod. 2008;23(12):2701–2708.
   PubMed Web of Science ®Google Scholar
• Seo SK, Nam A, Jeon YE, et al. Expression and possible role of non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) in the human endometrium and endometriosis. Hum Reprod. 2010;25(12):3043–3049.
   PubMed Web of Science ®Google Scholar
• Matsuzaki S, Canis M, Darcha C, et al. Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats. Fertil Steril. 2004;82(6):1609–1615.
   PubMed Web of Science ®Google Scholar
• Efstathiou JA, Sampson DA, Levine Z, et al. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril. 2005;83(1):171–181.
   PubMed Web of Science ®Google Scholar
• Olivares C, Ricci A, Bilotas M, et al. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril. 2011;96(2):428–433.
   PubMed Web of Science ®Google Scholar
• Zhang RJ, Wild RA, Ojago JM. Effect of tumor necrosis factor-α on adhesion of human endometrial stromal cells to peritoneal mesothelial cells: an in vitro system. Fertil Steril. 1993;59(6):1196–1201.
   PubMed Web of Science ®Google Scholar
• Braun DP, Ding J, Dmowski WP. Peritoneal fluid-mediated enhancement of eutopic and ectopic endometrial cell proliferation is dependent on tumor necrosis factor-α in women with endometriosis. Fertil Steril. 2002;78(4):727–732.
   PubMed Web of Science ®Google Scholar
• D’Hooghe TM, Nugent NP, Cuneo S, et al. Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Biol Reprod. 2006;74(1):131–136.
   PubMed Web of Science ®Google Scholar
• Falconer H, Mwenda JM, Chai DC, et al. Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon. Hum Reprod. 2006;21(7):1856–1862.
   PubMed Web of Science ®Google Scholar
• Yildirim G, Attar R, Ficicioglu C, et al. Etanercept causes regression of endometriotic implants in a rat model. Arch Gynecol Obstet. 2011;283(6):1297–1302.
   PubMed Web of Science ®Google Scholar
• Islimye M, Kilic S, Zulfikaroglu E, et al. Regression of endometrial autografts in a rat model of endometriosis treated with etanercept. Eur J Obstetrics Gynecol Reprod Biol. 2011;159(1):184–189.
   PubMed Web of Science ®Google Scholar
• Zulfikaroglu E, Kilic S, Islimye M, et al. Efficacy of anti-tumor necrosis factor therapy on endometriosis in an experimental rat model. Arch Gynecol Obstet. 2011;283(4):799–804.
   PubMed Web of Science ®Google Scholar
• Cayci T, Akgul EO, Kurt YG, et al. The levels of nitric oxide and asymmetric dimethylarginine in the rat endometriosis model. J Obstetrics Gynaecol Res. 2011;37(8):1041–1047.
   PubMed Web of Science ®Google Scholar
• Koninckx PR, Craessaerts M, Timmerman D, et al. Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod. 2008;23(9):2017–2023.
   PubMed Web of Science ®Google Scholar
• New L, Han J. The p38 MAP kinase pathway and its biological function. Trends Cardiovasc Med. 1998;8(5):220–228.
   PubMed Web of Science ®Google Scholar
• Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today. 1999;5(10):439–447.
   PubMedGoogle Scholar
• Yoshino O, Osuga Y, Hirota Y, et al. Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis. Am J Reprod Immunol. 2004;52(5):306–311.
   PubMed Web of Science ®Google Scholar
• Seval Y, Cakmak H, Kayisli UA, et al. Estrogen-mediated regulation of p38 mitogen-activated protein kinase in human endometrium. J Clin Endocrinol Metabolism. 2006;91(6):2349–2357.
   PubMed Web of Science ®Google Scholar
• Yoshino O, Osuga Y, Hirota Y, et al. Endometrial stromal cells undergoing decidualization down-regulate their properties to produce proinflammatory cytokines in response to interleukin-1β via reduced p38 mitogen-activated protein kinase phosphorylation. J Clin Endocrinol Metabolism. 2003;88(5):2236–2241.
   PubMed Web of Science ®Google Scholar
• Zhou WD, Yang HM, Wang Q, et al. SB203580, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis by down-regulating proinflammatory cytokines and proteolytic factors in a mouse model. Hum Reprod. 2010;25(12):3110–3116.
   PubMed Web of Science ®Google Scholar
• Yoshino O, Osuga Y, Koga K, et al. FR 167653, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis in a murine model. J Reprod Immunol. 2006;72(1–2):85–93.
   PubMed Web of Science ®Google Scholar
• Penning TM. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review. Expert Opin Ther Pat. 2017;27(12):1329–1340.
   PubMed Web of Science ®Google Scholar
• González-Ramos R, Van Langendonckt A, Defrre S, et al. Involvement of the nuclear factor-κB pathway in the pathogenesis of endometriosis. Fertil Steril. 2010;94(6):1985–1994.
   PubMed Web of Science ®Google Scholar
• Yagyu T, Kobayashi H, Matsuzaki H, et al. Thalidomide inhibits tumor necrosis factor-α-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-κB activation. J Clin Endocrinol Metabolism. 2005;90(5):3017–3021.
   PubMed Web of Science ®Google Scholar
• Huber AV, Saleh L, Prast J, et al. Human chorionic gonadotrophin attenuates NF-κB activation and cytokine expression of endometriotic stromal cells. Mol Hum Reprod. 2007;13(8):595–604.
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Xu ZM, Dai HY, et al. Application of the nuclear factor-κB inhibitor pyrrolidine dithiocarbamate for the treatment of endometriosis: an in vitro study. Fertil Steril. 2010;94(7):2942–2944.
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Xu ZM, Zhang CM, et al. Pyrrolidine dithiocarbamate inhibits nuclear factor-κB pathway activation, and regulates adhesion, migration, invasion and apoptosis of endometriotic stromal cells. Mol Hum Reprod. 2011;17(3):175–181.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li M, Wang F, et al. Endometriotic epithelial cells induce MMPs expression in endometrial stromal cells via an NFB-dependent pathway. Gynecol Endocrinol. 2010;26(6):456–467.
   PubMed Web of Science ®Google Scholar
• Nasu K, Nishida M, Ueda T, et al. Application of the nuclear factor-κB inhibitor BAY 11-7085 for the treatment of endometriosis: an in vitro study. Am J Physiol Endocrinol Metabolism. 2007;293(1):E16–E23.
   PubMed Web of Science ®Google Scholar
• Kim JH, Yang YI, Lee KT, et al. Costunolide induces apoptosis in human endometriotic cells through inhibition of the prosurvival Akt and nuclear factor kappa B signaling pathway. Biol Pharm Bull. 2011;34(4):580–585.
   PubMed Web of Science ®Google Scholar
• Choudhuri T, Pal S, Das T, et al. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem. 2005;280(20):20059–20068.
   PubMed Web of Science ®Google Scholar
• Swarnakar S, Paul S. Curcumin arrests endometriosis by downregulation of matrix metalloproteinase-9 activity. Indian J Biochemistry Biophys. 2009;46(1):59–65.
   PubMed Web of Science ®Google Scholar
• Kim KH, Lee EN, Park JK, et al. Curcumin attenuates TNF-α-induced expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and proinflammatory cytokines in human endometriotic stromal cells. Phytotherapy Res. 2012;26(7):1037–1047.
   PubMed Web of Science ®Google Scholar
• Jana S, Paul S, Swarnakar S. Curcumin as anti-endometriotic agent: implication of MMP-3 and intrinsic apoptotic pathway. Biochem Pharmacol. 2012;83(6):797–804.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cao H, Hu YY, et al. Inhibitory effect of curcumin on angiogenesis in ectopic endometrium of rats with experimental endometriosis. Int J Mol Med. 2011;27(1):87–94.
   PubMed Web of Science ®Google Scholar
• Kizilay G, Uz YH, Seren G, et al. In vivo effects of curcumin and deferoxamine in experimental endometriosis. Adv Clin Exp Med. 2017;26(2):207–213.
   PubMed Web of Science ®Google Scholar
• Tandrasasmita OM, Sutanto AM, Arifin PF, et al. Anti-inflammatory, antiangiogenic, and apoptosis-inducing activity of DLBS1442, a bioactive fraction of Phaleria macrocarpa, in a RL95-2 cell line as a molecular model of endometriosis. Int J Womens Health. 2015;7:161–169.
   PubMed Web of Science ®Google Scholar
• Tjandrawinata RR, Nofiarny D, Susanto LW, et al. Symptomatic treatment of premenstrual syndrome and/or primary dysmenorrhea with DLBS1442, a bioactive extract of Phaleria macrocarpa. Int J Gen Med. 2011;4:465–476.
   PubMedGoogle Scholar
• Altintas D, Kokcu A, Kandemir B, et al. Efficacy of imiquimod, an immunomodulatory agent, on experimental endometriosis. Fertil Steril. 2008;90(2):401–405.
   PubMed Web of Science ®Google Scholar
• Palmer SS, Altan M, Denis D, et al. Bentamapimod (JNK Inhibitor AS602801) induces regression of endometriotic lesions in animal models. Reprod Sci. 2016;23(1):11–23.
   PubMed Web of Science ®Google Scholar
• Harlev A, Gupta S, Agarwal A. Targeting oxidative stress to treat endometriosis. Expert Opin Ther Targets. 2015;19(11):1447–1464.
   PubMed Web of Science ®Google Scholar
• Parazzini F, Vigano P, Candiani M, et al. Diet and endometriosis risk: a literature review. Reprod Biomed Online. 2013;26(4):323–336.
   PubMed Web of Science ®Google Scholar
• Dulak J, Józkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005;5(8):579–594.
   PubMed Web of Science ®Google Scholar
• Becker CM, Sampson DA, Rupnick MA, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril. 2005;84(SUPPL. 2):1144–1155.
   PubMed Web of Science ®Google Scholar
• Nasu K, Yuge A, Tsuno A, et al. Simvastatin inhibits the proliferation and the contractility of human endometriotic stromal cells: a promising agent for the treatment of endometriosis. Fertil Steril. 2009;92(6):2097–2099.
   PubMed Web of Science ®Google Scholar
• Bruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metabolism. 2009;94(7):2489–2494.
   PubMed Web of Science ®Google Scholar
• Oktem M, Esinler I, Eroglu D, et al. High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod. 2007;22(5):1474–1480.
   PubMed Web of Science ®Google Scholar
• Yilmaz B, Ozat M, Kilic S, et al. Atorvastatin causes regression of endometriotic implants in a rat model. Reprod Biomed Online. 2010;20(2):291–299.
   PubMed Web of Science ®Google Scholar
• Yilmaz B, Sucak A, Kilic S. Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9. Am J Obstet Gynecol. 2010;20:238e1–368e8.
   Google Scholar
• Lebovic DI, Mwenda JM, Chai DC, et al. Peroxisome proliferator-activated receptor-γ receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study. Endocrinology. 2010;151(4):1846–1852.
   PubMed Web of Science ®Google Scholar
• Lebovic DI, Mwenda JM, Chai DC, et al. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril. 2007;88(4SUPPL.):1108–1119.
   PubMedGoogle Scholar
• Lebovic DI, Kir M, Casey CL. Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril. 2004;82(SUPPL. 3):1008–1013.
   PubMed Web of Science ®Google Scholar
• Mariani M, Vigan P, Gentilini D, et al. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum Reprod. 2012;27(7):2010–2019.
   PubMed Web of Science ®Google Scholar
• Pavone ME, Reierstad S, Sun H, et al. Altered retinoid uptake and action contributes to cell survival in endometriosis. J Clin Endocrinol Metabolism. 2010;95(11):E300–E9.
   PubMed Web of Science ®Google Scholar
• Pavone ME, Dyson M, Reirstad S, et al. Endometriosis expresses a molecular pattern consistent with decreased retinoid uptake, metabolism and action. Hum Reprod. 2011;26(8):2157–2164.
   PubMed Web of Science ®Google Scholar
• Wieser F, Wu J, Shen Z, et al. Retinoic acid suppresses growth of lesions, inhibits peritoneal cytokine secretion, and promotes macrophage differentiation in an immunocompetent mouse model of endometriosis. Fertil Steril. 2012;97(6):1430–1437.
   PubMed Web of Science ®Google Scholar
• Rocha AL, Reis FM, Petraglia F. New trends for the medical treatment of endometriosis. Expert Opin Investig Drugs. 2012;21(7):905–919.
   PubMed Web of Science ®Google Scholar
• Netsu S, Konno R, Odagiri K, et al. Oral eicosapentaenoic acid supplementation as possible therapy for endometriosis. Fertil Steril. 2008;90(4SUPPL.):1496–1502.
   PubMedGoogle Scholar
• Tomio K, Kawana K, Taguchi A, et al. Omega-3 polyunsaturated fatty acids suppress the cystic lesion formation of peritoneal endometriosis in transgenic mouse models. PLoS ONE. 2013;8:9.
   Web of Science ®Google Scholar
• Akyol A, Simsek M, Ilhan R, et al. Efficacies of vitamin D and omega-3 polyunsaturated fatty acids on experimental endometriosis. Taiwan J Obstet Gynecol. 2016;55(6):835–839.
   PubMed Web of Science ®Google Scholar
• Signorile PG, Viceconte R, Baldi A. Novel dietary supplement association reduces symptoms in endometriosis patients. J Cell Physiol. 2018 Aug;233(8):5920-5925.
   PubMed Web of Science ®Google Scholar
• Porpora MG, Brunelli R, Costa G, et al. A promise in the treatment of endometriosis: an observational cohort study on ovarian endometrioma reduction by N-acetylcysteine. EvidBased Complement Altern Med. 2013;2013.
   PubMedGoogle Scholar
• Pinar N, Soylu Karapinar O, Ozcan O, et al. Effect of alpha-lipoic acid on endometrial implants in an experimental rat model. Fundam Clin Pharmacol. 2017;31(5):506–512.
   PubMed Web of Science ®Google Scholar
• Kolahdouz Mohammadi R, Arablou T. Resveratrol and endometriosis: in vitro and animal studies and underlying mechanisms (review). Biomed Pharmacother. 2017;91:220–228.
   PubMed Web of Science ®Google Scholar
• Maia H Jr., Haddad C, Pinheiro N, et al. Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. Int J Womens Health. 2012;4:543–549.
   PubMedGoogle Scholar
• Mendes da Silva D, Gross LA, Neto EPG, et al. The use of resveratrol as an adjuvant treatment of pain in endometriosis: a randomized clinical trial. J Endocr Soc. 2017;1(4):359–369.
   PubMed Web of Science ®Google Scholar
• Hsiao KY, Wu MH, Tsai SJ. Epigenetic regulation of the pathological process in endometriosis. Reprod Med Biol. 2017;16(4):314–319.
   PubMedGoogle Scholar
• Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713.
   PubMed Web of Science ®Google Scholar
• Liu XF, Bagchi MK. Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J Biol Chem. 2004;279(15):15050–15058.
   PubMed Web of Science ®Google Scholar
• Wu Y, Guo SW. Suppression of IL-1β-induced COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells. Eur J Obstetrics Gynecol Reprod Biol. 2007;135(1):88–93.
   PubMed Web of Science ®Google Scholar
• Wu Y, Guo SW. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur J Obstetrics Gynecol Reprod Biol. 2008;137(2):198–203.
   PubMed Web of Science ®Google Scholar
• Lu Y, Nie J, Liu X, et al. a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice. Hum Reprod. 2010;25(4):1014–1025.
   PubMed Web of Science ®Google Scholar
• Liu X, Yuan L, Guo SW. Valproic acid as a therapy for adenomyosis: a comparative case series. Reprod Sci. 2010;17(10):904–912.
   PubMed Web of Science ®Google Scholar
• Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017;107(3):533–536.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Buggio L, Berlanda N, et al. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril. 2016;106(7):1552–71 e2.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Abbamonte LH, Anserini P, et al. Future perspectives in the medical treatment of endometriosis. Obstet Gynecol Surv. 2005;60(12):817–826.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Ragni N, Remorgida V. Antiangiogenic therapies in endometriosis. Br J Pharmacol. 2006;149(2):133–135.
   PubMed Web of Science ®Google Scholar
• Barra F, Ferrero S. The use of retinoic acid for the treatment of endometriosis. Arch Gynecol Obstet. 2018; [cited 2018 May 16]:[2 p.] DOI: 10.1007/s00404-018-4774-9.
   Google Scholar
• Barra F, Ferrero S. mTor inhibitors for the treatment of endometriosis. Geburtshilfe Frauenheilkd. 2018;78(3):283–284.
   PubMed Web of Science ®Google Scholar
• Liu X, Guo SW. A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril. 2008;89(1):246–250.
   PubMed Web of Science ®Google Scholar
• Barra F, Ferrero S. Epigenetic Drugs in the Treatment of Endometriosis. Reprod Sci. 2018;  [cited 2018 May 16]:[2 p.] DOI: 10.1177/1933719118765987
   Google Scholar
• Guo SW, Olive DL. Two unsuccessful clinical trials on endometriosis and a few lessons learned. Gynecol Obstet Invest. 2007;64(1):24–35.
   PubMed Web of Science ®Google Scholar